NCT01072396 - Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease | Biotech Hunter

Enrollment

126

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Tiotropium

double blind randomized crossover

DRUG

Placebo

inhalation powder capsule identical to those containing tiotropium bromide inhalation powder

Trial Locations (15)

205.440.1006 Boehringer Ingelheim Investigational Site, Birmingham

205.440.1015 Boehringer Ingelheim Investigational Site, Jasper

205.440.1002 Boehringer Ingelheim Investigational Site, Torrance

205.440.1018 Boehringer Ingelheim Investigational Site, Hartford

205.440.1008 Boehringer Ingelheim Investigational Site, Springfield

205.440.1017 Boehringer Ingelheim Investigational Site, Muncie

205.440.1020 Boehringer Ingelheim Investigational Site, Livonia

205.440.1011 Boehringer Ingelheim Investigational Site, Lebanon

205.440.1019 Boehringer Ingelheim Investigational Site, Charlotte

205.440.1013 Boehringer Ingelheim Investigational Site, Pittsburgh

205.440.1007 Boehringer Ingelheim Investigational Site, Spartanburg

205.440.2003 Boehringer Ingelheim Investigational Site, Kingston

205.440.2001 Boehringer Ingelheim Investigational Site, Montreal

205.440.2004 Boehringer Ingelheim Investigational Site, Montreal

205.440.2002 Boehringer Ingelheim Investigational Site, Ste-Foy